Home · Stock · BMY

BMY Bristol-Myers Squibb Co

Which ETFs hold BMY? Bristol-Myers Squibb Co is held by 2 funds tracked by ETFpeek.

Held by 2 funds todayData as of 31 Aug 2026
HealthcareDrug Manufacturers - General
$59.58
+41.6% 1y
$42.5252-week range$68.64
Market cap
$124.9B
P/E
13.1
Dividend
4.23%
3-month
+4.5%
CEO
Dr. Christopher S. Boerner Ph.D.
Revenue · last 4 qtrs (+5.7% YoY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Provider

Currently Held By

VANGUARD
VOO
Weight in fund0.21%
Shares held54,253,514
Market value$3.62B
View fund →
SMARTSHARES
USF
Smart US 500 ETF
via VOO
Weight in fund0.21%
Shares held—
Market value$2.6M NZD
View fund →
Not held by the selected provider.
last 90 days
No notable insider activity in the last 90 days. Show all 7 trades
Net flow (90d):+$52K (1 without value)·6 BUY / 1 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
2 Oct 2026
Cari Gallman
Executive VP, General Counsel & Chief Policy Officer
BUYOption Exercise4,559—0
2 Oct 2026
Cari Gallman
Executive VP, General Counsel & Chief Policy Officer
SELLVested (RSU)2,332$143K0
30 Sep 2026
Theodore R. II Samuels
Director / Other
BUYVested (RSU)821$51K30
30 Sep 2026
Michael R. McMullen
Director / Other
BUYVested (RSU)561$35K30
30 Sep 2026
Derica W Rice
Director / Other
BUYVested (RSU)621$39K30
30 Sep 2026
Peter J Arduini
Director / Other
BUYVested (RSU)561$35K30
30 Sep 2026
Phyllis R Yale
Director / Other
BUYVested (RSU)561$35K30
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
0 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
No trades recorded yet.
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds